| 000 | 01838 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250518083705.0 | ||
| 264 | 0 | _c20210707 | |
| 008 | 202107s 0 0 eng d | ||
| 022 | _a1473-1150 | ||
| 024 | 7 |
_a10.1038/s41397-020-0159-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBruno, Christopher D | |
| 245 | 0 | 0 |
_aHLA associations with infliximab-induced liver injury. _h[electronic resource] |
| 260 |
_bThe pharmacogenomics journal _c10 2020 |
||
| 300 |
_a681-686 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadverse effects |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xdiagnosis |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenome-Wide Association Study |
| 650 | 0 | 4 |
_aHLA Antigens _xgenetics |
| 650 | 0 | 4 |
_aHLA-B39 Antigen _xgenetics |
| 650 | 0 | 4 |
_aHLA-B8 Antigen _xgenetics |
| 650 | 0 | 4 |
_aHLA-DQ beta-Chains _xgenetics |
| 650 | 0 | 4 |
_aHLA-DRB1 Chains _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfliximab _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPharmacogenomic Variants |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aFremd, Brandon | |
| 700 | 1 | _aChurch, Rachel J | |
| 700 | 1 | _aDaly, Ann K | |
| 700 | 1 | _aAithal, Guruprasad P | |
| 700 | 1 | _aBjörnsson, Einar S | |
| 700 | 1 | _aLarrey, Dominique | |
| 700 | 1 | _aWatkins, Paul B | |
| 700 | 1 | _aChow, Christina R | |
| 773 | 0 |
_tThe pharmacogenomics journal _gvol. 20 _gno. 5 _gp. 681-686 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41397-020-0159-0 _zAvailable from publisher's website |
| 999 |
_c30601976 _d30601976 |
||